IQ-AI Ltd (LON:IQAI) said it has received the regulatory green light in America for its StoneChecker software, which is used to assess kidney stones.
Imaging Biometrics, the company’s Milwaukee-based subsidiary, was granted “clearance to market” by the US Food & Drug Administration.
The company said it would issue an update outlining the scale of the opportunity along with its product roll-out plans in the next few days.
IQ-AI shares surged 41% to 6.65p on Friday morning.
-- Adds shares price --